Prothena Corporation plc

NASDAQ:PRTA

Biotechnology

Healthcare
$8.35 +3.89%

+$0.33 today

Market cap
$428.77M
Beta
-0.32
P/E (TTM)
-3.1
EPS (TTM)
-$2.81
52W Low $5.64High $11.80

Volume 0.76M

Average 0.51M

PRTA Other Working Capital

Cash effect of changes in other operating assets and liabilities.

Prothena Corporation plcNASDAQ: PRTA

Other Working Capital · Q1 FY2026 · quarter ended Mar 2026

Other working capital dips below year-ago levels

Q1 FY2026 other working capital of $4.26M (cash outflow) fell 0.2% year over year, behind the +121.2% change in trailing-twelve-month other working capital. Sequentially, it rose 18.5% from the prior quarter.

Context

  • Other working capital amounted to 119.8% of revenue in FY2025, up 79.3 pp from a year earlier.
  • Other working capital increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -0.2% toward the trailing-twelve-month pace of +121.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$4.26M+18.5% QoQ
Last fiscal yearDec 2025
$11.6M+121.2% YoY
LTMMar 2026
$11.61M+121.2% YoY
Other Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.2%——
1 year+121.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Working Capital history

USD · from the cash flow

Latest · FY2025
11.6M USD
Year-over-year change
+121.2%

Other Working Capital vs competitors

How PRTA compares with its peers on the latest reported figures

  • Peers report in different currencies, so other working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +121.2% is the highest of 10, against a peer median of -124.6%.
  • Other working capital amounts to 20.0% of revenue for PRTA, versus a peer median of 149.2%.
PRTA Competitors
Other Working Capital for PRTA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BIIBBiogen Inc.LTM Jun 2026$106.1M USD-86.4%+43.9%1.1%
DNLIDenali Therapeutics Inc.LTM Jun 2026$12.91M USD-128.5%—358.3%
PRTAProthena Corporation plcLTM Mar 2026$11.61M USD+121.2%—20.0%
ANNXAnnexon, Inc.LTM Mar 2026$9.76M USD-229.0%——
ACIUAC Immune S.A.LTM Dec 2025CHF 5.33M CHF-105.7%-9.1%149.2%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$4.68M USD-124.6%-55.3%—
AVXLAnavex Life Sciences Corp.LTM Dec 2025$4.51M USD-1220.1%——
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$4.04M USD-138.9%——
PMNProMIS Neurosciences, Inc.LTM Jun 2026$1.04M USD-26.6%+39.5%—
CGTXCognition Therapeutics, Inc.LTM Mar 2026$60K USD-94.3%-44.2%—
Peer median (excluding PRTA) —-124.6%-9.1%149.2%

Competitors are the stored peer set for PRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income66.98M(116.95M)(147.03M)(122.31M)(244.09M)
Depreciation & Amortization1.12M744K928K893K895K
Deferred Income Tax4.57M(11.13M)(15.69M)(9.35M)43.24M
Stock-Based Compensation24.66M31.32M40.91M45.96M37.64M
Change in Working Capital(10.4M)(18.8M)(20.53M)(67.94M)(4.17M)
Accounts Receivables15K0(5.16M)5.16M0
Inventory00(8.9M)00
Accounts Payables(492K)11.87M22.86M(18.3M)(15.78M)
Other Working Capital(9.93M)(30.67M)(29.33M)(54.8M)11.6M
Other Non-Cash Items5.69M6M7.5M2.69M2.91M
Operating Cash Flow92.61M(108.82M)(133.91M)(150.05M)(163.58M)
Capital Expenditures(575K)(464K)(2.81M)(298K)(138K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0037K00
Investing Cash Flow(575K)(464K)(2.77M)(298K)(138K)
Debt Repayment00000
Common Stock Issued174.79M223.62M23.58M0(139K)
Common Stock Repurchased000(353K)0
Dividends Paid00000
Other Financing Activities15.54M17.84M21.52M1.91M0
Financing Cash Flow190.33M241.46M45.1M1.55M(139K)
Effect of Forex Changes00000
Net Change in Cash282.36M132.17M(91.58M)(148.79M)(163.86M)
Free Cash Flow92.03M(109.29M)(136.72M)(150.35M)(163.72M)

Prothena Corporation plc

NASDAQ:PRTA

Intrinsic Alpha fair value

Locked

Current Price

$8.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.